See more : Samsung Electro-Mechanics Co., Ltd. (009150.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Instil Bio, Inc. (TIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Instil Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fawaz Abdulaziz Al Hokair & Company (4240.SR) Income Statement Analysis – Financial Results
- Brookfield Asset Management Inc. (BAM-A.TO) Income Statement Analysis – Financial Results
- Apollo Silver Corp. (APGO.V) Income Statement Analysis – Financial Results
- Shinozakiya, Inc. (2926.T) Income Statement Analysis – Financial Results
- China Oceanwide Holdings Limited (0715.HK) Income Statement Analysis – Financial Results
Instil Bio, Inc. (TIL)
About Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 138.00K | 0.00 |
| Cost of Revenue | 4.76M | 5.99M | 2.75M | 0.00 | 20.00K |
| Gross Profit | -4.76M | -5.99M | -2.75M | 138.00K | -20.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 39.60M | 141.06M | 107.25M | 19.40M | 4.03M |
| General & Administrative | 47.55M | 62.24M | 48.31M | 14.38M | 2.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.55M | 62.24M | 48.31M | 14.38M | 2.56M |
| Other Expenses | 72.01M | -564.00K | -1.20M | -4.66M | -5.00K |
| Operating Expenses | 85.79M | 203.29M | 155.56M | 33.78M | 6.59M |
| Cost & Expenses | 90.54M | 203.29M | 155.56M | 33.78M | 6.59M |
| Interest Income | 8.87M | 3.66M | 0.00 | 70.00K | 68.00K |
| Interest Expense | 5.21M | 1.88M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.76M | 5.99M | 2.75M | 256.00K | 20.00K |
| EBITDA | -146.12M | -217.38M | -154.00M | -33.39M | -6.50M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -24,660.14% | 0.00% |
| Operating Income | -159.17M | -226.46M | -155.56M | -33.64M | -6.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -24,379.71% | 0.00% |
| Total Other Income/Expenses | 3.08M | 1.21M | -1.20M | -3.94M | 63.00K |
| Income Before Tax | -156.09M | -225.25M | -156.76M | -37.59M | -6.52M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -27,236.96% | 0.00% |
| Income Tax Expense | 0.00 | -2.07M | 39.00K | 151.00K | -68.00K |
| Net Income | -156.09M | -223.18M | -156.79M | -37.74M | -6.45M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -27,346.38% | 0.00% |
| EPS | -24.00 | -34.46 | -24.30 | -5.89 | -1.01 |
| EPS Diluted | -24.00 | -34.46 | -24.30 | -5.89 | -1.01 |
| Weighted Avg Shares Out | 6.50M | 6.48M | 6.45M | 6.41M | 6.41M |
| Weighted Avg Shares Out (Dil) | 6.50M | 6.48M | 6.45M | 6.41M | 6.41M |
Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharmaceuticals, retaining commercialization rights outside Greater China and enhancing its global market positioning. SYN-2510 is advancing...
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov....
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soared because it's developing a bispecific antibody similar...
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday.
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line...
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 testing, but a similar candidate from Summit Therapeutics recently outperformed...
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond...
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights...
Source: https://incomestatements.info
Category: Stock Reports